The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / B Cell Receptor Clones May Predict RA Onset

B Cell Receptor Clones May Predict RA Onset

August 15, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Scientists know that plasma and B cells play important roles in the pathogenesis of rheumatoid arthritis (RA). However, not all individuals with RA-specific antibodies clinically manifest RA. This phenomenon is puzzling and leaves healthcare professionals in need of a test that can be used to identify patients who will develop RA symptoms. Such a test may make it possible to design and implement effective strategies for early prevention.

You Might Also Like
  • B Cell-Directed Therapy May Delay RA Development in High-Risk Patients
  • Histamine 4 Receptor Promotes Osteoclastogenesis in RA
  • More Evidence Biomarkers Predict RA Relapse with DMARD Taper
Also By This Author
  • Metabolic Profiling of SLE

For individuals at risk for RA, research indicates that dominant B cell receptor (BCR) clones in peripheral blood may predict the onset of clinical signs and symptoms of RA. These clones initially present in the periphery and can be found in the synovial tissue after symptoms manifest. Paul P. Tak, MD, PhD, professor of clinical immunology and rheumatology at the University of Amsterdam in the Netherlands, and colleagues say their data are consistent with the hypothesis that these clones shift from peripheral blood to target tissue during the onset of RA. Their results were published in the August 2017 issue of the Annals of Rheumatic Disease.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Their data “show the presence of increased BCR clonal  signatures in peripheral blood obtained during the preclinical stage of RA,” write the authors in their discussion. “During onset of arthritis, these BCR clones disappear from blood and appear in the target tissue, where they may drive autonomous disease progression. Our observations show the presence of dominant BCR clones in peripheral blood in the at-risk stage accurately predicts short-term onset of clinically manifest disease.”

In the study, the investigators included 129 patients with joint pain and RA-specific antibodies. All patients had clinically manifest arthritis at the time of the second synovial biopsy. The researchers measured the peripheral blood BCRheavy chain repertoire at the mRNA level. This group could be divided into individuals who tested positive with at least five dominant BCR clones (n=45) and those who tested negative (n=84). They found that patients who had at least five dominant BCR clones in peripheral blood were likely to experience short-term onset of RA within 36 months.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers also found the patients with more BCR clones were at higher risk of imminent-onset arthritis. When the investigators looked specifically at patients who had at least nine clones, they found that, in about half of these patients, disease developed after approximately a year. Almost all of these patients had RA at 3.5 years. All told, the results suggest that a simple blood test may be able to predict which patients at risk for RA will go on to develop it in the next three years. The new biomarker may have better predictive power than previously identified biomarkers.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: B cell receptor clones, B cells, Rheumatoid Arthritis (RA)

You Might Also Like:
  • B Cell-Directed Therapy May Delay RA Development in High-Risk Patients
  • Histamine 4 Receptor Promotes Osteoclastogenesis in RA
  • More Evidence Biomarkers Predict RA Relapse with DMARD Taper
  • Healthy Clones: Dolly the Sheep’s Heirs Reach Ripe Old Age

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)